A collaborative effort to evaluate treatment of liver and pancreatic tumors
HOUSTON, DENVER and CHICAGO ? The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy.
Under the agreement, MD Anderson and TriSalus will collaborate on studies evaluating the administration of investigational SD-101 intravascularly via TriSalus Food and Drug Administration (FDA) cleared, proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology across a range of liver and pancreatic solid tumors.
MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.